



07/508109

Merz 16/bam

Applicants: Joachim Bormann, Markus R. Gold, Wolfgang Schatton

Title: Adamantane-Derivatives in the Prevention and Treatment  
of Cerebral Ischemia

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)

"Express Mail" No.: RB481160603 Date of Deposit: 4-11-90  
I hereby certify that this paper is being deposited with the United  
States Postal Service "Express Mail Post Office to Addressee" service  
under 37 CFR 1.10 on the date indicated above and is addressed to the  
Commissioner of Patents and Trademarks, Washington, D. C. 20231.

Beth A. Mitchell  
Name of person mailing paper

Beth A. Mitchell  
Signature



370.00 -101-A

07/508109


501

NP  
WK

ADAMANTANE DERIVATIVES IN  
THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA

SyP

The present invention relates to a method for the prevention or treatment of cerebral ischemia using an adamantane derivative of the following general formula



(I)

15 RS

wherein <sup>po</sup>R<sub>1</sub> and R<sub>2</sub> are identical or different and represent hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic radical with 5 or 6 ring C atoms;

10  
ps wherein <sup>po</sup>R<sub>3</sub> and R<sub>4</sub> are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; and

5 ps wherein <sup>po</sup>R<sub>5</sub> is hydrogen or a straight or branched C<sub>1</sub> - <sub>14</sub> C<sub>6</sub> alkyl group, or a pharmaceutically-acceptable acid addition salt thereof. Herein branched or straight C<sub>1</sub> - <sub>14</sub> C<sub>6</sub> alkyl groups representatively include methyl, ethyl, iso- and n-propyl, n-, iso- and t-butyl, n-pentyl, n-hexyl, and the isomers thereof.

\* \* \* \* \*


p Certain 1-amino adamantanes of formula (I) are known. 1-amino-3,5-dimethyl adamantane, for example, is the subject matter of German patents 22 19 256 and 28 56 393.

15 Some 3,5-disubstituted 1-amino adamantanes of formula (I) are described in US Patent 4,122,193. 1-amino-3-ethyl adamantane is described in German Patent 22 32 735.

20 The compounds of formula (I) are generally prepared by alkylation of halogenated adamantanes, preferably bromo- or chloroadamantanes. The di- or tri-substituted adamantanes are obtained by additional halogenation and alkylation procedures. The amino group is introduced either by oxidation with chromiumtrioxide and bromination with HBr or bromination with bromine and reaction with formamide followed by hydrolysis. The amino function can be alkylated according to generally <sup>o</sup>accepted methods. Methylation can, for example, be effected by reaction with chloromethyl formate and subsequent reduction. The ethyl group can be introduced by reduction of the respective acetamide.

35

P In accordance with U.S. Patent <sup>No</sup> 4,122,193 amination can  
 also be effected by reaction of the respective  
 1-halogen-3,5- or -7-substituted adamantane with a  
 urea derivative of the formula




wherein R<sub>1</sub> is hydrogen or alkyl.

The compounds according to formula (I) are prepared according to  
 the following reaction scheme:

Reaction scheme

Ad = adamantyl group

Hal = Cl, Br



4

Alkylation of the halogenated adamantanes can be achieved by known methods, for example, through Friedel-Crafts reaction (introduction of phenyl group), or by reaction with vinylidene chloride, subsequent reduction and suitable Wittig reaction of the aldehydes and subsequent hydration, or by introduction of ethylene and subsequent alkylation with appropriate cuprates, or by introduction of ethylene and reduction of the halogen alkyl adamantanes, or by acylation with CO<sub>2</sub> and reduction of the carboxylic acid.

The compounds according to formula (I) known from the above-cited patents have so far been used for the treatment of parkinsonian and parkinsonoid diseases. Their mode of action is attributed to a dopaminergic influence on the CNS, either by an increased release of the transmitter substance dopamine or by an inhibition of its uptake. This compensates the imbalance of the dopamine / acetylcholine system.

In contrast to this type of disease, cerebral ischemia is characterized by a pathophysiological situation defined by an imbalance of neuronal stimulation mechanisms. In this context, the excessive inflow of calcium through NMDA receptor channels finally leads to the destruction of brain cells in specific brain areas (Rothmann & Olney, Trends Neurosci 10, 1989, pp. 299).

Therefore, in order to treat or eliminate this pathological situation, an antagonistic intervention is required with regard to the NMDA receptor channels (Kemp et al., Trends Pharmacol., Sci. 8, 1987. pp. 414).

Such intervention can, for example, be effected using substituted fluoro and hydroxy derivatives of dibenzo-[a,d]-cyclo-heptene-5,10-imine which are described in EP-A 0 264 183.

These heterocyclic, aromatic compounds are lipophilic and exhibit NMDA receptor channel-antagonistic and anticonvulsive properties. They are prepared by a relatively expensive method generating enantiomer mixtures which may be split into the individual optical antipodes.

p The present invention is aimed at preparing and employing compounds which can be chemically generated by simple methods, exhibiting an NMDA receptor channel-antagonistic and anticonvulsive action, for use in the prevention and treatment of cerebral ischemia.

This objective can be achieved according to the invention by using the 1-amino adamantanes of formula (I).

It has been found unexpectedly that the use of these compounds prevents an impairment or further impairment, i.e., degeneration and loss of nerve cells, after ischemia. Therefore, the adamantane derivatives of formula (I) are especially suited for the prevention and treatment of cerebral ischemia after apoplexy, open-heart surgery, cardiac standstill, subarachnoidal hemorrhage, transient cerebro-ischemic attacks, perinatal asphyxia, anoxia, hypoglycemia, apnoea and Alzheimer's disease. The amount employed is a cerebral ischemia-alleviating or preventive amount.

Examples of compounds prepared and used according to the invention are:

1-amino adamantane  
1-amino-3-phenyl adamantane  
1-amino-methyl-adamantane  
1-amino-3,5-dimethyl adamantane (test compound no. 1)  
1-amino-3-ethyl adamantane (test compound no. 2)  
1-amino-3-isopropyl adamantane (test compound no. 3)  
1-amino-3-n-butyl adamantane  
1-amino-3,5-diethyl adamantane (test compound no. 4)  
1-amino-3,5-diisopropyl adamantane  
1-amino-3,5-di-n-butyl adamantane  
1-amino-3-methyl-5-ethyl adamantane  
1-N-methylamino-3,5-dimethyl adamantane (test compound no. 5)  
1-N-ethylamino-3,5-dimethyl adamantane (test compound no. 6)  
1-N-isopropyl-amino-3,5-dimethyl adamantane  
1-N,N-dimethyl-amino-3,5-dimethyl adamantane  
1-N-methyl-N-isopropyl-amino-3-methyl-5-ethyl adamantane

PO

	1-amino-3-butyl-5-phenyl adamantane	
	1-amino-3-pentyl adamantane	
	1-amino-3,5-dipentyl adamantane	
	1-amino-3-pentyl-5-hexyl adamantane	
5	1-amino-3-pentyl-5-cyclohexyl adamantane	
	1-amino-3-pentyl-5-phenyl adamantane	
	1-amino-3-hexyl adamantane	
	1-amino-3,5-dihexyl adamantane	
	1-amino-3-hexyl-5-cyclohexyl adamantane	
10	1-amino-3-hexyl-5-phenyl adamantane	
	1-amino-3-cyclohexyl adamantane	(test compound no. 7)
	1-amino-3,5-dicyclohexyl adamantane	
	1-amino-3-cyclohexyl-5-phenyl adamantane	
	1-amino-3,5-diphenyl adamantane	
15	1-amino-3,5,7-trimethyl adamantane	
	1-amino-3,5-dimethyl-7-ethyl adamantane	(test compound no. 8)
	1-amino-3,5-diethyl-7-methyl adamantane	
	1-N-pyrrolidino and 1-N-piperidine derivatives,	
	1-amino-3-methyl-5-propyl adamantane	
20	1-amino-3-methyl-5-butyl adamantane	
	1-amino-3-methyl-5-pentyl adamantane	
	1-amino-3-methyl-5-hexyl adamantane	
	1-amino-3-methyl-5-cyclohexyl adamantane	
	1-amino-3-methyl-5-phenyl adamantane	
25	1-amino-3-ethyl-5-propyl adamantane	
	1-amino-3-ethyl-5-butyl adamantane	
	1-amino-3-ethyl-5-pentyl adamantane	
	1-amino-3-ethyl-5-hexyl adamantane	
	1-amino-3-ethyl-5-cyclohexyl adamantane	
30	1-amino-3-ethyl-5-phenyl adamantane	

10 1-amino-3-propyl-5-butyl adamantane  
1-amino-3-propyl-5-pentyl adamantane  
1-amino-3-propyl-5-hexyl adamantane  
1-amino-3-propyl-5-cyclohexyl adamantane  
5 1-amino-3-propyl-5-phenyl adamantane  
1-amino-3-butyl-5-pentyl adamantane  
1-amino-3-butyl-5-hexyl adamantane  
1-amino-3-butyl-5-cyclohexyl adamantane

Ps their N-methyl, N,N-dimethyl, N-ethyl, N-propyl deriva-  
10 tives and their acid addition compounds.

Preferred compounds of formula (I) are those wherein R<sub>1</sub> and R<sub>2</sub> are  
hydrogen such as, for example, 1-amino-3-ethyl-5,7-dimethyl ada-  
mantane, and compounds wherein R<sub>1</sub>, R<sub>2</sub>, R<sub>4</sub> and R<sub>5</sub> are hydrogen such  
15 as, for example, 1-amino-3-cyclohexyl adamantane and 1-amino-3-  
ethyl adamantane.

Additional preferred compounds are those wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub>  
are hydrogen such as, for example, 1-amino-3-methyl-5-propyl or  
20 5-butyl adamantane, 1-amino-3-methyl-5-hexyl or cyclohexyl ada-  
mantane, or 1-amino-3-methyl-5-phenyl adamantane.

Especially preferred compounds are  
1-amino-3,5-dimethyl adamantane, 1-amino-3,5-diethyl adamantane,  
25 i.e., compounds wherein R<sub>1</sub>, R<sub>2</sub> and R<sub>3</sub> are hydrogen, and compounds  
wherein R<sub>1</sub> and R<sub>3</sub> are hydrogen, R<sub>2</sub> is methyl or ethyl, and R<sub>4</sub> and  
R<sub>5</sub> are methyl such as, for example, 1-N-methylamino-3,5-dimethyl  
adamantane and 1-N-ethylamino-3,5-dimethyl adamantane.

30 The adamantane derivatives of formula (I) may be  
applied as such or in the form of their pharmaceutically  
acceptable acid addition salts including, for example,  
the hydrochlorides, hydrobromides, sulfates, acetates,  
succinates or tartrates, or their acid addition salts  
35 with fumaric, maleic, citric, or phosphoric acids.



1 The compounds of formula (I) are administered in  
suitable form in doses ranging from about 0.01 to 100  
mg/kg. Appropriate presentation forms are, for example,  
5 combinations of the active substance with common  
pharmaceutical carriers and adjuvants in the form of  
tablets, coated tablets, and sterile solutions or  
suspensions for injection. Pharmaceutically-acceptable  
carriers are, for example, lactose, sucrose, sorbitol,  
10 talc, stearic acid, magnesium stearate, gum arabic,  
corn starch, or cellulose, combined with diluents such  
as water, polyethylene glycol, etc. Solid presentation  
forms are prepared according to common methods and may  
contain up to 50 mg of the active ingredient per  
unit.

15 The efficacy of the compounds of formula (I) is described in the  
following pharmacological tests.

20 CC A. Displacement of TCP binding

14 Phencyclidine (PCP), a known NMDA antagonist, binds to the NMDA  
receptor-associated ionic channel and blocks ionic transport  
14 (Garthwaite & Garthwaite, Neurosci. Lett. 83, 1987, 241-246). Ad-  
ditionally, PCP has been shown to prevent the destruction of brain  
25 cells after cerebral ischemia in rats (Sauer et al., Neurosci.  
14 Lett. 91, 1988, 327-332).

The interaction between compounds of formula (I) and the PCP bond  
is studied in the following. In this test <sup>3</sup>H-TCP, a PCP analogue,  
30 is used.

A membrane preparation of rat cortex is incubated with <sup>3</sup>H-TCP  
which is an analogue of phencyclidine (PCP) (Quirion & Pert 1982,  
Eur.J. Pharmacol. 83:155). The interaction with the TCP binding is  
assessed for test compound no. 1 (1-amino-3,5-dimethyl adamantane)  
35 in a competitive experiment. This test shows that compound no. 1  
is very effective in displacing TCP from the bond. The IC<sub>50</sub> value  
is 89 nM. The conclusion can be drawn that compound no. 1 binds to  
NMDA receptor channels at the same site as the NMDA antagonist  
PCP.

cc B. Blocking of NMDA receptor channels

f In the following test it is shown that the compounds of formula (I) according to the invention are as effective as PCP in blocking the NMDA receptor channel.

5 In the patch-clamp experiment, the current flowing through NMDA-activated membrane channels of cultivated spinal marrow neurons (mouse) is measured (Hamill et al 1981, Pflügers Arch. 312: 85-100). After application of 20  $\mu$ M NMDA, the current signal of the cell is integrated for 20 sec. and recorded as a control answer ( $A_c$ ). During succeeding application of 20  $\mu$ M NMDA and 6  $\mu$ M of an adamantane derivative, the intensity of the substance effect can be determined as a relative change of the control answer ( $A/A_c - A =$  test answer).

10 14,82 82 31 15 The results are summarized in the following Table 1:

20 Table 1

Compound no.	1-A/ $A_c$	n
1	0.66 $\pm$ 0.05	14
2	0.44 $\pm$ 0.08	7
3	0.58 $\pm$ 0.07	7
4	0.50 $\pm$ 0.11	5
5	0.56 $\pm$ 0.07	7
6	0.38 $\pm$ 0.05	7
7	0.25 $\pm$ 0.04	11
8	0.50 $\pm$ 0.03	6
PCP	0.50 $\pm$ 0.04	7
MK-801	0.60 $\pm$ 0.05	22

35 The values are given as means  $\pm$  SEM.

10

As can be seen from the results, the aminoadamantane derivatives of formula (I) are able to block the NMDA receptor channel as has been described for PCP (Bertolini et al., Neurosci. Lett. 84, 1988, 351-355) and for 5-methyl-10,11-dihydro-5H-dibenzo[a,d]-cycloheptene-5,10-imine (MK-801) (EP-A 0 264 183).

C. Anticonvulsive effect

4, 12, 36, 108 and 324 mg/kg of the test substance is administered to mice by the intraperitoneal route (5 animals per dose). The supermaximum electroshock test is applied forty (40) minutes after application of the substance to investigate the anti-convulsive potential of the substance. The protected animals are added up over all dosages (score; maximum = 25 animals).

The results are given in the following Table 2.

Table 2

Compound no.	Anticonvulsive action (score)	Mean	ED <sub>50</sub> (mg/kg)
1	18 16 16 15	16.3	16
2	15 14 12	13.7	30
4	16 16 11	14.3	24
5	17 17	17.0	13
Standards:			
PCP	19	19.0	9
MK-801	25	25.0	< 1

The ED<sub>50</sub> values were estimated according to Litchfield, J.T. and Wilcoxon, F., J. Pharmacol. Exp. Therap. 96, 99-113 (1949).

p As can be seen from the above results, aminoadamantane derivatives of formula (I) exhibit a protective effect against electrically induced convulsions. They therefore have an anticonvulsive effect.

5 CL D. Correlation between channel-blocking and anticonvulsive action

p  
14 The correlation between the action of the tested adamantane derivatives 1-8 at the NMDA receptor channel (in vitro) and the anticonvulsive effect (in vivo) has been tested. For this purpose an xy diagram of both test parameters is plotted. It shows that there is a correlation between the blocking of the NMDA receptor channel and the anticonvulsive action of the adamantanes of formula (I).

15 CL E. Protection against cerebral ischemia

p  
20 14 Both carotid arteries are occluded in rats for 10 minutes. At the same time the blood pressure is reduced to 60-80 mg Hg by withdrawal of blood (Smith et al. 1984, Acta Neurol. Scand. 69: 385, 401). The ischemia is terminated by opening the carotids and reinfusion of the withdrawn blood. After seven days the brains of the test animals are histologically examined for cellular changes in the CA1-CA4 region of the hippocampus, and the percentage of destroyed neurons is determined. The action of test compound No. 1 is determined after a single administration of 5 mg/kg and 20 mg/kg one (1) hour prior to the ischemia.

30

12

The results are summarized in the following Table 3:

Table 3

Area	Control	Test compound no. 1	
		5 mg/kg (n=5)	20 mg/kg (n=6)
CA1	80.2 ± 1.5	83.0 ± 2.2	53.1 ± 6.1**
CA3	3.6 ± 1.1	7.3 ± 1.8	2.7 ± 1.0
CA4	1.4 ± 0.4	3.7 ± 1.7	0.6 ± 0.3

The values are given in percent of damaged neurons ± SEM.  
Significance of the mean difference: \*\*p < 0.01 (U test)

The results show that the reduction of the post-ischemic neuronal brain damage in the CA1 region of the rat hippocampus is statistically significant after the pre-ischemic application of 20 mg/kg of test compound no. 1. Physiological parameters (e.g. blood pressure, body temperature) are not affected by the treatment. Moreover, the results show that the compounds according to formula (I) exhibit a neuroprotective action in cerebral ischemia.

Essentially the same result is attained by employing the compounds of the other Examples, especially those designated test compounds 2-8.

#### F. Protection Against NMDA-Induced Mortality

It is well known that, subsequent to cerebral ischemia, glutamate and aspartate levels increase massively in the brain. These excitatory aminoacids overstimulate the NMDA-subtype of the glutamate receptor thus leading to delayed neuronal death. A similar pathophysiological situation is obtained when mice are administered intraperitoneally with 200 mg/kg NMDA. This high dose will eventually cause 100% mortality in the animals (Leander et al. 1984, Brain Res. 448; 115-120). We

have found that the adamantane derivatives of the present invention are protective against the NMDA<sup>6</sup> induced mortality.

5	<u>Compound No.</u>	<u>Dose mg/kg</u>	<u>Protected Animals</u>
	1	50	8/8
		25	6/8
		10	3/8
	3	50	6/8
		25	4/8
10	4	50	7/8
		25	5/8
	5	25	5/8

T, 140X  
15 In the control animals, to which no adamantane was administered, the mortality was eight (8) animals out of eight (8).

CC  
20 G. Displacement of [<sup>3</sup>H] MK-801 Binding in Human Brain Tissue <sup>8 9</sup>

P MK-801 binds to the ion channel associated with the NMDA receptor, as well as TCP does. This binding site is thought to mediate the neuroprotective effects of non-competitive NMDA-antagonists.

25 We have investigated whether the adamantane derivatives of the present invention are active at the MK-801 binding site. Tissue from frontal cortex was taken from patients at autopsy and homogenates were prepared.

30 8,9 Inhibition of specific [<sup>3</sup>H] MK-801 binding (3nM) by the test compounds was determined (see e.g. Kornhuber  
14 et al. 1989, Eur. J. Pharmacol. 166: 589-590).

P The test compounds were highly potent in displacing MK-801 binding, thus indicating a specific interaction with the NMDA receptor channel and predicting neuroprotective properties.

5

<u>Compound No.</u>	<u>Ki nM</u>
1	536
3	598
4	189
5	1607

10 T<sub>1/50</sub>X

Ps wherein K<sub>i</sub> is the inhibition constant and nM is nanomoles per liter. Mean values from triplicate  
3S experiments are given  $\pm$  S.E.M.

15

20

The inhibition constant K<sub>i</sub> is approximately equal to the concentration of the adamantane in nM required to displace 50% of the MK-801 specifically bound to the receptor. In this regard, memantine (Compound No. 1) was found to be the most potent compound subjected to this test, when compared with thirteen (13) other clinically-used and centrally-acting drugs, as reported in the foregoing publication.

DE, 25P

The invention is further described by the following illustrative examples, which are not to be construed as limiting:

CLK

Example 1

30

Injectable solution

P

For preparing a 0.5% solution, dissolve 0.5% active ingredient and 0.8% sodium chloride (DAB 9) in doubly distilled water. Filter the solution through an antimicrobial filter, fill into 2-ml ampoules and sterilize for 20 minutes at 120°C in an autoclave.

35

15

2042  
L  
P  
Example 2  
Solution

5 Dissolve 1% of active agent in demineralized water. Filter the solution before filling.

2042  
L  
Example 3  
Tablets

1 tablet contains:

10 Active ingredient 10.0 mg  
Lactose 67.5 mg  
Microcrystalline cellulose 18.0 mg  
Talc 4.5 mg  
-----  
15 100.0 mg

P The substances are mixed and the mixture compressed into 100-mg tablets in a direct tableting procedure without granulation.

20  
2042  
L  
Example 4  
Coated tablets

P  
25 Prepare 6-mm tablet cores of 100 mg as described under "Tablets". Coat the tablets in a sugar-coating process by coating the core with a sugar suspension first, followed by staining with a colored syrup and polishing.

The tablet coating consists of:

30 Sugar 65.0 mg  
Talc 39.0 mg  
Calcium carbonate 13.0 mg  
Gum arabic 6.5 mg  
Corn starch 3.7 mg  
Shellac 1.1 mg  
35 Polyethylene glycol 6000 0.2 mg  
Magnesia usta 1.3 mg  
Dye 0.2 mg  
-----  
130.0 mg

Total tablet weight: 230 mg



244/ Example 5

P For preparing a 0.01% infusion solution, dissolve 0.01% of active ingredient and 5% levulose in doubly-distilled water. Filter the solution through an antimicrobial filter, fill into 500-ml infusion bottles, and sterilize.

The example provides 50 mg of active substance per single dose.

10 244/ Example 6

↓ Synthesis of 1-amino-3-isopropyl adamantane hydrochloride  
(test compound no. 3)

CC A. Preparation of adamantane methyl carboxylate (I)

15 P Stir 1.0 mol of adamantane carboxylic acid in 600 ml of methanol. Under ice cooling, drop 1.53 mol of acetyl chloride into the solution within 1 h. Remove the ice bath, and allow the reaction mixture to reach room temperature. Subsequently, heat for 3 hrs under reflux. Evaporate the reaction mixture to dryness under vacuum and  
20 distill. (Yield: 97 %)①

CC B. Preparation of isopropyl adamantane (II)

P Introduce 0.5 mol of magnesium chips into 50 ml of absolute ether,  
25 and drop 0.5 mol of methyl iodide into the solution under moisture free conditions until the ether boils. Subsequently, heat in a water bath until the magnesium has completely dissolved. Into this solution at room temperature drop 0.2 mol of adamantane methyl carboxylate in absolute ether. Then  
30 heat to reflux for 3 hours. After cooling, hydrolyze with ice and mix with ammonium chloride solution until the precipitate has dissolved. Separate the ether phase, wash the aqueous phase with 2 portions of ether, and wash the combined organic phases with sodium  
35 bicarbonate solution. Then dry and evaporate to dryness under vacuum. (Yield: 93%)②

17

c C. Preparation of isopropene adamantane (III)

p Stir 0.25 mol of isopropyl adamantane (II) in 500 ml acetic anhydride for 12 hours at 160°C. Subsequently, pour the reaction mixture onto 1 liter of ice water and extract with ether. Dry the combined organic phases with magnesium sulfate, filter, and evaporate to dryness under vacuum. Distill the residue under vacuum. (Yield: 66%)

10 c C D. Preparation of isopropyl adamantane (IV)

p Dissolve 0.074 mol of adamantyl isopropene (III) in 100 ml of absolute ethanol. Add 4 g of palladium (5 % on activated carbon) and hydrate under stirring for 24 hrs at room temperature. Subsequently, filter off the catalyst, and remove the solvent under vacuum. Δ (Yield: 91 %)

20 c C E. Preparation of 1-bromo-3-isopropyl adamantane (V)

p Mix 0.034 mol of isopropyl adamantane (IV) with a ten times excess of bromine (0.33 mol). Heat slowly and stir under reflux for 4 h. Subsequently, allow to cool and pour onto ice water. Decompose the excess bromine with sodium sulfite until the aqueous solution has discolored. Then extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 83 %)

30 c C F. Preparation of 1-H-formyl-3-isopropyl adamantane (VI)

p Heat 0.028 mol of 1-bromo-3-isopropyl adamantane (V) with 40 ml of formamide to reflux for 12 hrs. After cooling, pour the reaction mixture onto water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness under vacuum. (Yield: 82 %)

CC G. Preparation of 1-amino-3-isopropyl adamantane hydrochloride

P Mix 0.023 mol of 1-N-formyl-3-isopropyl adamantane (VI) with 100 ml of 15 % hydrochloric acid and heat to boiling for 24 hrs. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 57 %) ①

CC/L Example 7

10 L Synthesis of 1-amino-3-cyclohexyl adamantane hydrochloride  
(test compound no. 7)

CC A. Preparation of 1-phenyl adamantane (I)

15 P Heat 0.068 mol of iron(III) chloride to boiling in 20 ml of absolute benzene. Drop 0.0186 mol of 1-bromo-adamantane, dissolved in 30 ml of absolute benzene, to the solution. Then heat to boiling for 3 hrs. After cooling, pour the reaction mixture onto ice/hydrochloric acid, separate the organic phase, and extract the aqueous phase with two portions of benzene. Wash the combined organic phases with water, dry with calcium chloride, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. ΔC  
(Yield: 80 %) ②

CC B. Preparation of 1-hydroxy-3-phenyl adamantane (II)

P To a solution of 0.03 mol chromiumtrioxide in 20 ml glacial acetic acid and 20 ml acetic anhydride, add 0.0095 mol of 1-phenyl adamantane at 0°C and stir for 24 hours at 4°C. Pour the reaction mixture onto water and extract with three portions of pentane. Wash the organic phase with saturated sodium chloride solution, dry over magnesium sulfate, filter and evaporate to dryness under vacuum. Hydrolyze the residue with 20 ml of 2N NaOH and 50 ml of methanol. Subsequently, remove the methanol under vacuum and dilute the residue with water. Then extract with three portions of ether. Dry

the organic phase, filter and evaporate to dryness under vacuum. Recrystallize the residue from cyclohexane. (Yield: 50 %)Ⓞ

5 H Ref.: H. Stetter, M. Schwarz, A. Hirschhorn, Chem. Ber. (1959), 92, 1629-35.

CC C. Preparation of 1-bromo-3-phenyl adamantane (III)

f

10 Stir 0.03 mol of 3-phenyl adamantanol (II) with 100 ml of 40 % HBr in glacial acetic acid for 20 min at 60°C and 30 min at room temperature. Subsequently, dilute the reaction mixture with water and extract with ether. Wash the combined organic extracts with sodium chloride solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from  
15 methanol. (Yield: 68 %)Ⓞ

Ref.: W. Fischer, C.A. Grog, Helvetica Chim. Acta (1976), 59, 1953.

20 CC D. Preparation of 1-N-formyl-3-phenyl adamantane (IV)

f

Heat 0.03 mol of 1-bromo-3-phenyl adamantane (III) with 50 ml of formamide for 12 hrs to reflux. After cooling, pour the reaction mixture onto water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate  
25 to dryness under vacuum. (Yield: 80 %)Ⓞ

CC E. Preparation of 1-amino-3-phenyl adamantane hydrochloride (V)

30 f

Heat 0.02 mol of 1-N-formyl-3-phenyl adamantane (IV) with 100 ml of 15% hydrochloric acid at reflux for 24 hours. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 60%)Ⓞ

CC F. Preparation of 1-amino-3-cyclohexyl adamantane (VI)

p Dissolve 0.011 mol of 1-amino-3-phenyl adamantane (V) in 150 ml  
glacial acetic acid, mix with 0.3 g of platinum oxide (1% on  
5 activated carbon) and hydrate in a Parr apparatus at 35°C at a  
hydrogen pressure of 3 bar. Subsequently, remove the catalyst by  
filtration and evaporate the filtrate to dryness. Take up the  
residue in methanol and precipitate the product with ether. Suck  
off and dry. Δ 2  
10 (Yield: 70 %)ⓐ

CC/ Example 8

15 Synthesis of 1-amino-3,5-dimethyl-7-ethyl adamantane hydrochloride  
(test compound no. 8)

CC A. Preparation of 1-bromo-3,5-dimethyl adamantane (I)

p Mix 0.5 mol of 1,3-dimethyl adamantane with a ten times excess  
20 of bromine (5 mol). Slowly heat and stir for 4 hrs under reflux.  
Subsequently, allow to cool and pour onto ice water. Decompose the  
excess bromine with sodium sulfite until discoloration of the  
aqueous solution. Then extract with ether, wash the combined or-  
ganic phases with sodium bicarbonate solution, dry with magnesium  
25 sulfate, filter and evaporate to dryness under vacuum. Recrystal-  
lize the residue from methanol. (Yield: 83 %) ⓐ

CC B. Preparation of 1-(2-bromoethyl)-3,5-dimethyl adamantane (II)

30 p Mix 1.4 mol of 1-bromo-3,5-dimethyl adamantane (I) in hexane with  
31 0.6 mol of aluminum bromide at -75°C. Subsequently, pass ethylene  
14 through the solution for 20 - 30 minutes, stir for 5 min., and  
pour the reaction mixture onto ice water. Extract with ether, dry  
the organic phase and evaporate to dryness. Recrystallize the  
35 residue from methanol. (Yield: 48 %)ⓐ

21

CC C. Preparation of 1,3-dimethyl-5-ethyl adamantane (III)

P Dissolve 0.5 mol of 1-(2-bromoethyl)-3,5-dimethyl adamantane (II) in toluene, mix with 0.55 mol of sodium-bis(2-methoxy-ethoxy)-  
5 dihydro aluminate, and heat to boiling for 3 hrs. After hydro-  
lysis, separate the organic phase, dry with magnesium sulfate,  
and evaporate to dryness under vacuum. Purify the residue by  
vacuum distillation. (Yield: 86 %)Ⓔ

10 CC D. Preparation of 1-bromo-3,5-dimethyl-7-ethyl adamantane (IV)

P Mix 0.4 mol of 1,3-dimethyl-5-ethyl adamantane (III) with a  
ten times excess of bromine (4 mol). Heat slowly and stir for 4  
hrs under reflux. Subsequently allow to cool and pour onto ice  
15 water. Decompose the excess bromine with sodium sulfite until dis-  
colouration of the aqueous solution. Then extract with ether, wash  
the combined organic phases with sodium bicarbonate solution, dry  
with magnesium sulfate, filter and evaporate to dryness under  
vacuum. Recrystallize the residue from methanol. (Yield: 86 %)Ⓔ

20

CC E. Preparation of 1-N-formyl-3,5-dimethyl-7-ethyl adamantane (V)

P Heat 0.2 mol of 1-bromine-3,5-dimethyl-7-ethyl adamantane (IV)  
with 150 ml of formamide at reflux for 12 hrs. After cooling, pour  
25 the reaction mixture onto water and extract with dichloromethane.  
Dry the combined organic phases with magnesium sulfate, filter and  
evaporate to dryness under vacuum. (Yield: 82 %)Ⓔ

CC F. Preparation of 1-amino-3,5-dimethyl-7-ethyl adamantane hydro-  
30 chloride (VI)

P Mix 0.2 mol of 1-N-formyl-3,5-dimethyl-7-ethyl adamantane (V) with  
100 ml of 15% hydrochloric acid and heat to boiling for 24 hrs.  
After cooling, filter the precipitate and recrystallize from iso-  
35 propanol. (Yield: 57%)Ⓔ

awc  
↓  
Example 9

Synthesis of 1-N-methylamino-3,5-dimethyl adamantane  
(test compound no. 5)

5  
p Dissolve 0.1 mol of the appropriately substituted amino adamantane (1-amino-3,5-dimethyl adamantane) with 0.15 mol of chloromethyl formate and potassium carbonate in acetone and heat to reflux for 8 hrs. After cooling, filter the solution, remove the solvent and  
10 dry the residue. Mix the raw product (0.05 mol) with 0.1 mol of sodium-bis-(2-methoxy-ethoxy)-dihydro aluminate in toluene and heat at reflux for 3 hrs. After cooling, hydrolyze with dilute HCl, dry the organic phase and evaporate to dryness. Purify the raw material by distillation.

15  
ccw  
↓  
Example 10

Synthesis of 1-amino-3-ethyl-5-phenyl adamantane

20  
A. Preparation of 1-bromo-3-ethyl adamantane (I)

p Mix 0.034 mol of ethyl adamantane with a ten times excess of bromine (0.33 mol). Heat slowly and stir under reflux for 4 hrs. Then allow to cool and pour onto ice water. Decompose the excess  
25 bromine with sodium sulfite until discoloration of the aqueous solution. Subsequently extract with ether, wash the combined organic phases with sodium bicarbonate solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 83 %) ②

30  
cc B. Preparation of 1-ethyl-3-phenyl adamantane (II)

p Heat 0.068 mol of iron(III) chloride in 20 ml of absolute benzene to boiling. Drop 0.0186 mol of 1-bromo-3-ethyl adamantane (I),  
35 dissolved in 30 ml of absolute benzene, into the solution. Then heat

at reflux for 3 hrs. After cooling, pour the reaction mixture onto ice/hydrochloric acid, separate the organic phase, and extract with two portions of benzene. Wash the combined organic phases with water, dry with calcium chloride, filter and evaporate to dryness. Recrystallize the residue from methanol. (Yield: 80 %) <sup>ⓐ</sup>

CL C. Preparation of 1-ethyl-3-hydroxy-5-phenyl adamantane (III)

P To a solution of 0.03 mol of chromiumtrioxide, in 20 ml glacial acetic acid and 20 ml acetic anhydride, add 0.0095 mol of 1-ethyl-3-phenyl adamantane (II) at 0°C and stir for 24 hours at 4°C. Pour the reaction mixture into water and extract with three portions of pentane. Wash the organic phase with saturated sodium chloride solution, dry over magnesium sulfate, filter and evaporate to dryness under vacuum. Hydrolize the residue with 20 ml of 2N NaOH and 50 ml of methanol. Remove the methanol under vacuum and dilute the residue with water. Then extract with three portions of ether. Dry the organic phase, filter and evaporate to dryness under vacuum. Recrystallize the residue from cyclohexane. (Yield: 50%) <sup>ⓐ</sup>

Ref.: H. Stetter, M. Schwarz, A. Hirschhorn, Chem. Ber. (1959), 92, 1629-35.

CL D. Preparation of 1-bromo-3-ethyl-5-phenyl adamantane (IV)

P Stir 0.03 mol of 1-ethyl-3-hydroxy-5-phenyl adamantane (III) with 100 ml of 40% HBr in glacial acetic acid for 20 min at 60°C and for 30 min at room temperature. Subsequently dilute the reaction mixture with water and extract with ether. Wash the combined organic extracts with sodium chloride solution, dry with magnesium sulfate, filter and evaporate to dryness under vacuum. Recrystallize the residue from methanol. (Yield: 68%) <sup>ⓐ</sup>

Ref.: W. Fischer, C.A. Grog, Helvetica Chim. Acta (1976), 59, 1953;



cc E. Preparation of 1-N-formyl-3-ethyl-5-phenyl adamantane (V)

5 ¶ Heat 0.03 mol of 1-ethyl-3-hydroxy-5-phenyl adamantane (IV) with 50 ml of formamide for 12 hrs at reflux. After cooling, pour the reaction mixture into water and extract with dichloromethane. Dry the combined organic phases with magnesium sulfate, filter and evaporate to dryness. (Yield: 80%)<sup>(d)</sup>

10 cc F. Preparation of 1-amino-3-ethyl-5-phenyl adamantane hydrochloride (VI)

15 ¶ Heat 0.02 mol of 1-N-formyl-3-ethyl-5-phenyl adamantane (V) with 100 ml of 15 % hydrochloric acid for 24 hrs at reflux. After cooling, filter the precipitate and recrystallize from isopropanol. (Yield: 60 %)<sup>(d)</sup>

20 It is thus seen that certain adamantane derivatives, some of which are novel, have been provided for the prevention and treatment of cerebral ischemia, and that pharmaceutical compositions embodying such an adamantane derivative have been provided for use in the prevention and treatment of cerebral ischemia, the amount of the said adamantane derivative provided in either case being a cerebral ischemia-alleviating or preventive amount.

30 Various modifications and equivalents will be apparent to one skilled in the art and may be made in the compounds, compositions, methods, and procedures of the present invention without departing from the spirit or scope thereof, and it is therefore to be understood that the invention is to be limited only by the full scope which can be legally attributed to the appended claims.

35

25